Business
Jazz Pharmaceuticals Showcases Impact of Sleep Medicine Portfolio at Psych Congress 2023
Six presentations demonstrated Jazz's commitment to providing solutions for people living with difficult-to-treat sleep disorders Review of multiple clinical
About this update from Jazz Pharmaceuticals Plc
[{"type":"text","content":"Six presentations demonstrated Jazz's commitment to providing solutions for people living with difficult-to-treat sleep disorders\nReview of multiple clinical trials provided a comprehensive analysis showing that oxybate improves sleep quality, sleep architecture and measures of disrupted nighttime sleep in narcolepsy, independent of once- or twice-nightly dosing\nDUBLIN, Sept. 11, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six abstracts presenting data from across its sleep medicine portfolio were featured at the 36th annual Psych Congress, held September 6-10, 2023. One of the accepted abstracts provided a comprehensive review of clinical data that assessed the impact of oxybate on sleep quality, sleep architecture and measures of disrupted nighttime sleep in narcolepsy. Oxybate is the active ingredient in Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution.\nThis review encompassed key data from five clinical studies that evaluated all high-sodium oxybates, fixed-dose and twice-nightly administrations, in both oxybate-experienced patients and those who had not undergone prior treatment. The review found that oxybate improved measures of sleep architecture and disrupted nighttime sleep in narcolepsy patients, independent of dosing regimen or prior oxybate experience.\n\"These compelling data add to the growing body of literature that looks at the effects of oxybate therapy in terms of sleep quality, sleep architecture and daytime function,\" said Richard K. Bogan, MD, FCCP, FAASM, associate clinical professor at the University of South Carolina School of Medicine and Medical University of South Carolina in Charleston, South Carolina. \"The review found that there was no significant difference in the improvement of sleep quality between oxybate dosing schedules. This is an important endpoint, as many patients utilize the twice-nightly dosing to individualize treatment of their sleep disorder.\"\nOther highlights from Psych Congress 2023 included:\nIn narcolepsy:A subgroup analysis from the Phase 3 study of Xywav in adults with narcolepsy, which found that the treatment's safety and efficacy were similar in those with and without psychiatric comorbidities, including depression and anxiety, and that there were no signals for the occurrence of new psychiatric disorders i...